https://scholars.lib.ntu.edu.tw/handle/123456789/594876
Title: | Evolution of systemic treatment for advanced hepatocellular carcinoma | Authors: | Wu T.-C. YING-CHUN SHEN ANN-LII CHENG |
Issue Date: | 2021 | Publisher: | John Wiley and Sons Inc | Journal Volume: | 37 | Journal Issue: | 8 | Start page/Pages: | 643-653 | Source: | Kaohsiung Journal of Medical Sciences | Abstract: | Advanced hepatocellular carcinoma (HCC) was considered an inherently refractory tumor in the chemotherapy era (1950–2000). However, systemic therapy has evolved to molecular targeted therapy and immunotherapy, and nine treatment regimens have been approved worldwide during the past 20 years. The approved regimens target tumor angiogenesis or tumor immunity, the two cancer hallmarks. Recently, the combination of atezolizumab (antiprogrammed cell death ligand 1) and bevacizumab (anti-vascular endothelial growth factor) has improved the efficacy of systemic therapy in treating advanced HCC without excessive toxicities or deterioration of quality of life. This review summarizes the major advances in systemic therapy and provides future perspectives on the next-generation systemic therapy for advanced HCC. ? 2021 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109342678&doi=10.1002%2fkjm2.12401&partnerID=40&md5=82a446124f04de1e7bc814f629861131 https://scholars.lib.ntu.edu.tw/handle/123456789/594876 |
ISSN: | 1607-551X | DOI: | 10.1002/kjm2.12401 | SDG/Keyword: | angiogenesis inhibitor; antineoplastic agent; antineoplastic monoclonal antibody; cytotoxic agent; cytotoxic T lymphocyte antigen 4 antibody; gilvetmab; immune checkpoint inhibitor; unclassified drug; vasculotropin receptor inhibitor; angiogenesis inhibitor; antineoplastic agent; advanced cancer; antiangiogenic therapy; cancer chemotherapy; cancer combination chemotherapy; cancer immunotherapy; history of medicine; human; liver cell carcinoma; molecularly targeted therapy; monoclonal antibody therapy; Review; systemic therapy; immunotherapy; liver cell carcinoma; liver tumor; procedures; vascularization; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.